256
Views
10
CrossRef citations to date
0
Altmetric
Original Research

12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus

, , , , , , , & show all
Pages 141-151 | Published online: 09 Oct 2018

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Ahmed H Abdelhafiz. (2023) Effects of hypoglycaemic therapy on frailty: a multi-dimensional perspective. Expert Review of Endocrinology & Metabolism 18:1, pages 53-65.
Read now
Hiroyuki Ito, Suzuko Matsumoto, Takuma Izutsu, Eiji Kusano, Shinya Nishio, Shinichi Antoku, Tomoko Yamasaki, Toshiko Mori, Michiko Togane, Shigenori Ando & Emiko Tsugami. (2019) Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity 12, pages 1783-1794.
Read now
Elizabeth Mary Lamos, Maka Hedrington & Stephen N Davis. (2019) An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors. Expert Opinion on Drug Safety 18:8, pages 691-701.
Read now

Articles from other publishers (7)

Sabiya Samim Khan, Gopal L. Khatik & Ashok K. Datusalia. (2023) Strategies for Treatment of Disease-Associated Dementia Beyond Alzheimer's Disease: An Update. Current Neuropharmacology 21:2, pages 309-339.
Crossref
Jiro Ogura & Hiroaki Yamaguchi. (2022) The Effectiveness of Antidiabetic Drugs in Treating Dementia: A Peek into Pharmacological and Pharmacokinetic Properties. International Journal of Molecular Sciences 23:12, pages 6542.
Crossref
Mengxi Yang, Di Sun, Yu Wang, Mengwen Yan, Jingang Zheng & Jingyi Ren. (2022) Cognitive Impairment in Heart Failure: Landscape, Challenges, and Future Directions. Frontiers in Cardiovascular Medicine 8.
Crossref
Jonathan V. Mui, Jiandong Zhou, Sharen Lee, Keith Sai Kit Leung, Teddy Tai Loy Lee, Oscar Hou In Chou, Shek Long Tsang, Abraham Ka Chung Wai, Tong Liu, Wing Tak Wong, Carlin Chang, Gary Tse & Qingpeng Zhang. (2021) Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis. Frontiers in Cardiovascular Medicine 8.
Crossref
A Young Sim, Sumit Barua, Jong Youl Kim, Yong-ho Lee & Jong Eun Lee. (2021) Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus. Frontiers in Neuroscience 15.
Crossref
Jinsha Liu, Joey Paolo Ting, Shams Al-Azzam, Yun Ding & Sepideh Afshar. (2021) Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases. International Journal of Molecular Sciences 22:6, pages 2805.
Crossref
Agnieszka Jankowska, Anna Wesołowska, Maciej Pawłowski & Grażyna Chłoń-Rzepa. (2020) Diabetic Theory in Anti-Alzheimer’s Drug Research and Development - Part 1: Therapeutic Potential of Antidiabetic Agents. Current Medicinal Chemistry 27:39, pages 6658-6681.
Crossref